# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $...
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $90 to ...
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price tar...